CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.
Home/Biomarker

VHL mutation / loss

Gene: VHL · Type: mutation

Indications: Renal cell carcinoma, VHL disease

Evidence Level Distribution

Level B: 7Level C: 492Level D: 1
LevelTypeDirectionSignificanceDiseaseDrugsRating
BPrognosticSupportsBetter OutcomeClear Cell Renal Cell Carcinoma4
CPredictiveSupportsSensitivity/ResponseChuvash PolycythemiaRuxolitinib4
CPredisposingSupportsPredispositionVon Hippel-Lindau Disease4
CPredisposingSupportsPredispositionVon Hippel-Lindau Disease4
BPredictiveDoes Not SupportSensitivity/ResponseRenal Cell CarcinomaAnti-VEGF Monoclonal Antibody4
CPredisposingSupportsPredispositionVon Hippel-Lindau Disease4
CPredisposingSupportsPredispositionVon Hippel-Lindau Disease4
CPredisposingSupportsPredispositionVon Hippel-Lindau Disease4
CPredisposingSupportsPredispositionVon Hippel-Lindau Disease4
CPredisposingSupportsPredispositionVon Hippel-Lindau Disease4
CPredisposingSupportsPredispositionVon Hippel-Lindau Disease4
CPredisposingSupportsPredispositionVon Hippel-Lindau Disease4
CPredisposingSupportsPredispositionVon Hippel-Lindau Disease4
CPredisposingSupportsPredispositionVon Hippel-Lindau Disease4
CPredisposingSupportsPredispositionVon Hippel-Lindau Disease4
CPredisposingSupportsPredispositionVon Hippel-Lindau Disease4
CPredisposingSupportsPredispositionVon Hippel-Lindau Disease4
CPredisposingSupportsPredispositionVon Hippel-Lindau Disease4
CPredisposingSupportsPredispositionVon Hippel-Lindau Disease4
CPredisposingSupportsPredispositionVon Hippel-Lindau Disease4